Inventor · disambiguated record
Cristina De Min
Also filed as: DE MIN CRISTINA
7 granted patents·2 pending applications·11 citations·filing 2016–2024
79Inventor score
Top patents by PatentIndex Score
9 records- 0187US11034760B2Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of CXCL9 and other biomarkersSWEDISH ORPHAN BIOVITRUM AG·Filed 2016·Granted Jun 15, 2021·4 cites·17 claims
- 0286US11236158B2Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indicationsSWEDISH ORPHAN BIOVITRUM AG·Filed 2020·Granted Feb 1, 2022·2 cites·6 claims
- 0385US11091543B2Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indicationsSWEDISH ORPHAN BIOVITRUM AG·Filed 2017·Granted Aug 17, 2021·3 cites·9 claims
- 0482US2025101095A1Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indicationsSWEDISH ORPHAN BIOVITRUM AG·Filed 2024·Application pending·0 cites
- 0580US12297264B2Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indicationsSWEDISH ORPHAN BIOVITRUM AG·Filed 2023·Granted May 13, 2025·0 cites·10 claims
- 0675US10556960B2Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkersNOVIMMUNE SA·Filed 2017·Granted Feb 11, 2020·2 cites·18 claims
- 0774US12195530B2Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indicationsSWEDISH ORPHAN BIOVITRUM AG·Filed 2021·Granted Jan 14, 2025·0 cites·17 claims
- 0863US12275785B2Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of CXCL9 and other biomarkersSWEDISH ORPHAN BIOVITRUM AG·Filed 2020·Granted Apr 15, 2025·0 cites·10 claims
- 0951US2023114594A1New therapeutic use of anakinra for covid-19SWEDISH ORPHAN BIOVITRUM AB PUBL·Filed 2021·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →